Navigation Links
Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
Date:11/14/2013

ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today announced that SYN-004, Synthetic Biologics' product candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in the infectious disease area. This selection was made through Elsevier Business Intelligence's panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The Company also announced that Jeffrey Riley, CEO, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19, 2013 at 4:00pm (EST) at the Hyatt Regency in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with conference attendees on Tuesday and Wednesday, November 19 and 20, 2013.

About Elsevier Business Intelligence and the Therapeutic Area Partnerships Conference

Elsevier Business Intelligence provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing a combination of news and information together with penetrating insight and analysis.

Organized by Elsevier Business Intelligence, the 2013 Therapeutic Area Partnerships (TAP) conference is designed to bring together biopharmaceutical industry decision makers to assess the most promising drug programs available for partnering in the following therapeutic areas: oncology, cardiovascular/metabolic diseases, neuroscience, infectious diseases, anti-inflammatory/autoimmune diseases and advanced therapies. For more information, please visit the conference website at http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.

About Synthetic Biologics, Inc.

Synthetic Biologics (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
2. China Synthetic Resin Industry Report, 2013-2016
3. Synthetic Biologics to Report Third Quarter 2013 Financial Results
4. Atlantic Peptides, a Synthetic Peptide Manufacturer, Unveils Its New Website for Easier Navigation
5. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
6. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
7. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
8. Synthetic Biologics to Report Second Quarter 2013 Financial Results
9. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
10. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
11. Synthetic Biologics to Present at OneMedForum New York 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):